成都亚中生物制药

Chengdu Yazhong Biological Pharmaceutical is a specialized biopharmaceutical manufacturer based in Chengdu, China, focusing on the production of plasma-derived therapies. Established in 1998, the company operates a GMP-certified facility capable of processing human plasma into a variety of life-saving treatments. Its primary product offerings include human albumin, intravenous immunoglobulin (IVIG), and specialized hyperimmune globulins for conditions such as Hepatitis B, Tetanus, and Rabies. Since its acquisition by China Biologic Products Holdings (CBPO) in 2013, the company has been a key component of one of China's largest plasma product networks. Yazhong Bio serves the healthcare market by providing essential blood products used in critical care, immunology, and infectious disease management.